Delayed Medicines To Hit Irish Market, But Uncertainty Remains For Future
Executive Summary
Nine new approved treatments that have faced delays in getting to Irish patients should hit the market this year, says the Health Service Executive. The innovative pharmaceutical industry welcomes the move but is calling for clear political direction on future processes.
You may also be interested in...
Takeda Eyes Irish Opportunities Despite Access Issues
The Japanese drug maker has invested steadily in its operations in Ireland and is looking to expand further.
Switching, Substitution & Quotas: Irish Govt Wants Views On Boosting Biosimilars
Stakeholders are being asked to respond to a consultation on what steps can be taken to increase the use of biosimilars in Ireland. The generics and biosimilars industry body Medicines for Ireland has welcomed the move but says it has come very late in the day.
Switching, Substitution & Quotas: Irish Govt Wants Views On Boosting Biosimilars
Stakeholders are being asked to respond to a consultation on what steps can be taken to increase the use of biosimilars in Ireland. The generics and biosimilars industry body Medicines for Ireland has welcomed the move but says it has come very late in the day.